Worth reading
60In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
2800000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise status of the 17th Series of Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment Clause)
発行・処分する株式数
Number of shares delivered during the month: 2,800,000 shares (new shares: 2,800,000; transferred treasury shares: 0)
Intended allottee
EVO FUND (allottee at the time of issuance)
発行済株式総数
Exercise ratio subject to exercise restrictions: 3.64% (2,800,000 shares / 76,933,798 shares)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise price in March 2026: ¥54.0–¥60.0 (with Exercise Price Adjustment Clause)
Number of Stock Acquisition Rights
Total issued: 192,000; exercised during the month: 28,000; unexercised as of the end of the month preceding the subject month: 65,800; unexercised as of the end of the subject month: 37,800
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
25 August 2025: Issuance of the 17th Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause), with EVO FUND as the allottee (total issued: 192,000)
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status of the 17th Series of Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment Clause) |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: 2,800,000 shares (new shares: 2,800,000; transferred treasury shares: 0) |
| Intended allottee | EVO FUND (allottee at the time of issuance) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 3.64% (2,800,000 shares / 76,933,798 shares) |
| Total number of issued shares | 89,554,098 shares (as of the end of the month preceding the subject month, including 63 treasury shares) → Not disclosed |
| Exercise price | Exercise price in March 2026: ¥54.0–¥60.0 (with Exercise Price Adjustment Clause) |
| Number of Stock Acquisition Rights | Total issued: 192,000; exercised during the month: 28,000; unexercised as of the end of the month preceding the subject month: 65,800; unexercised as of the end of the subject month: 37,800 |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | 25 August 2025: Issuance of the 17th Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause), with EVO FUND as the allottee (total issued: 192,000) |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This disclosure reports the monthly exercise status; the company has not provided an explanation of the reasons for the exercises.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.